Cardiovascular Systems Stock

Cardiovascular Systems Liabilities

Delisted

The The Liabilities of Cardiovascular Systems (CSII) as of Aug 26, 2026 is 73.20 M USD. In the previous year, The Liabilities was 81.61 M USD — a change of -10.31% (lower).

Liabilities

73.20 MUSD

YoY

-10.31%

Last updated:

In 2026, Cardiovascular Systems's total liabilities amounted to 73.20 M USD, a -10.31% difference from the 81.61 M USD total liabilities in the previous year.

The Cardiovascular Systems Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2015
31.89 M USD
Jan 1, 2016
41.51 M USD
Jan 1, 2017
75.55 M USD
Jan 1, 2018
68.88 M USD
Jan 1, 2019
70.63 M USD
Jan 1, 2020
70.73 M USD
Jan 1, 2021
81.61 M USD
Jan 1, 2022
73.20 M USD
The Cardiovascular Systems Liabilities history
YEARLiabilitiesYoY
73.20 MUSD-10.31%
81.61 MUSD+15.39%
70.73 MUSD+0.13%
70.63 MUSD+2.54%
68.88 MUSD-8.83%
75.55 MUSD+82.01%
41.51 MUSD+30.15%
31.89 MUSD+6.86%
29.85 MUSD
Access this data via the Eulerpool API

Cardiovascular Systems Stock analysis

What does Cardiovascular Systems do? Cardiovascular Systems Inc. (CSI) is a US medical technology company founded in 1989. The company is headquartered in St. Paul, Minnesota and employs approximately 1,000 employees worldwide. CSI develops, manufactures, and distributes innovative devices for the treatment of vascular diseases. The business model of CSI is based on the development and marketing of medical devices for minimally invasive treatment of vascular diseases. The company generates a significant portion of its revenues through the sale of its products to hospitals and specialized healthcare facilities. Additionally, CSI also offers training and educational programs for doctors and medical personnel to optimize the use of their devices. CSI operates in two main segments: peripheral arterial disease (PAD) and coronary heart disease (CHD). The PAD segment includes devices for the treatment of vascular diseases outside of the heart, such as peripheral arterial occlusive disease (PAOD). This includes the Diamondback-360® catheter and the Stealth 360® catheter, both used for plaque ablation in the arteries. The CHD segment focuses on the treatment of heart diseases such as coronary artery disease (CAD). This includes the Orbital Atherectomy System (OAS), a device that can reduce the use of stents in patients with more severe coronary artery narrowings. CSI's core product is the Diamondback-360® catheter, which was approved by the US Food and Drug Administration (FDA) in 2013. This device consists of a rotating catheter inserted into the artery to remove plaque causing vessel narrowing. The Diamondback-360 catheter is used for the treatment of PAD and has the potential to significantly improve patients' quality of life. Another important product from CSI is the Orbital Atherectomy System (OAS), used for the treatment of CAD. The OAS system is a rotating catheter that can remove plaque in the coronary arteries to improve blood flow. The use of OAS can potentially avoid costly and invasive procedures such as coronary angiography or bypass. In summary, Cardiovascular Systems Inc. is a leading company in the development and production of innovative devices for minimally invasive treatment of vascular diseases. The company specializes in two main segments, peripheral arterial disease and coronary heart disease. With products like the Diamondback-360 catheter and the Orbital Atherectomy System, CSI has established itself as a reliable provider of high-quality medical devices. Through training and educational programs, CSI also contributes to improving medical care and the development of treatment methods. Cardiovascular Systems is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Cardiovascular Systems's Liabilities

Cardiovascular Systems's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Cardiovascular Systems's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Cardiovascular Systems's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Cardiovascular Systems's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Cardiovascular Systems’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Cardiovascular Systems stock

The Liabilities of Cardiovascular Systems is 73.20 M USD in 2026.

The Liabilities of Cardiovascular Systems changed from 81.61 M USD to 73.20 M USD, representing a -10.31% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Cardiovascular Systems since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Cardiovascular Systems historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Cardiovascular Systems

All Key Metrics — Cardiovascular Systems